Collagenase Clostridium Histolyticum - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The collagenase Clostridium histolyticum market is expected to grow from USD 140.70 million in 2025 to reach USD 150.06 million in 2026 and is forecasted to reach USD 211.54 million by 2031, growing at a CAGR of 7.11% from 2026 to 2031. This report is segmented by Indication (Dupuytren's Contracture, Peyronie's Disease, Cellulite, and More), Formulation (Liquid, Lyophilized), End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, Rest of the World). The Market Forecasts are Provided in Terms of Value (USD).

Global Collagenase Clostridium Histolyticum Market Trends and Insights

Rising Prevalence and Diagnosis of Fibrotic Hand and Urological Disorders

Dupuytren's disease was reported at a 1.99% point prevalence in Dutch primary care, with an incidence of 1.72 per 1,000 person-years. The same study showed a higher prevalence in men and a peak among men aged 71 to 80 years. This age pattern supports sustained demand for the collagenase Clostridium histolyticum market as more patients are screened and referred for hand and urological conditions. Better diagnostic capture can increase treated volumes even where underlying disease prevalence changes slowly. The broader fibrosis burden may also keep attention on enzyme-based approaches across related conditions.

Shift Toward Minimally Invasive, Office-Based Treatment

CCH offers a non-surgical option for patients who may otherwise undergo open procedures or percutaneous needle treatment. A review of 11 studies involving 1,443 patients found comparable efficacy between CCH and percutaneous needle fasciotomy. Office-based administration can reduce the need for anesthesia and hospital resources. This care model fits providers seeking shorter recovery periods and lower facility use. The collagenase Clostridium histolyticum market benefits where clinicians have been trained to administer injections safely. Certification requirements can still slow the shift in areas without formal training programs.

Serious Procedure-Related Injury and Hypersensitivity Risk

Safety concerns can affect both prescriber confidence and patient willingness to consider CCH. A 2025 review comparing CCH with limited fasciectomy reported a higher recurrence risk for CCH and identified higher rates of hematoma, local pain, and edema in several studies. Hypersensitivity reactions and the risk of tendon rupture require providers to select and monitor patients carefully. These risks may weigh more heavily in community settings with less experience in managing complications. The FDA's REMS requirements reinforce the need for trained prescribers and appropriate handling. The collagenase Clostridium histolyticum market may therefore remain concentrated in specialized settings even as new indications emerge.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of CCH into New Fibrotic Indications
• Increasing Specialist Familiarity and Procedure Standardization
• High Per-Course Treatment Cost and Reimbursement Friction

Segment Analysis

Dupuytren's contracture accounted for 41.72% of the 2025 collagenase Clostridium histolyticum market. Its established clinical use and broad prescriber base make it the main revenue contributor. Dutch primary-care evidence reported a 1.99% prevalence of Dupuytren's disease, with a strong association with older age. The condition is particularly relevant in North America and Northern Europe, where diagnosis pathways and trained providers are more developed. Plantar fibromatosis is an emerging opportunity rather than a current approved core use. Other potential uses include frozen shoulder and related fibrotic conditions that remain investigational.

Peyronie's disease is projected to grow at a 7.51% CAGR through 2031, the fastest rate among indications. Keenova stated in January 2026 that 100,000 Peyronie's disease patients had been treated with XIAFLEX. The condition has limited evidence-backed enzymatic alternatives, which supports the position of CCH within its approved population. Updated evidence found comparable outcomes when CCH was used in acute and stable disease phases. Earlier treatment could increase patient volumes if clinical guidance reflects this evidence. The collagenase Clostridium histolyticum market also benefits from awareness activities that reach patients and partners who may not otherwise seek care. This wider recognition may help reduce underdiagnosis in a condition that has often remained untreated.

Complete Report Scope:

• By Indication
  • Dupuytren's Contracture
  • Peyronie's Disease
  • Cellulite
  • Other Indications
• By Formulation
  • Liquid
  • Lyophilized
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World

Geography Analysis

North America accounted for 48.26% of the collagenase Clostridium histolyticum market in 2025. The region benefits from FDA-approved treatment pathways, established specialty pharmacies, and a large trained provider base. Keenova reported USD 546.3 million in XIAFLEX net sales for FY2025 and USD 134 million for Q1 2026, which was 11% higher year over year. The United States drives regional use, while Canada and Mexico have less developed coverage for injectable treatments in these indications.

Europe has an established regulatory base but uneven patient access. The European Medicines Agency authorized XIAPEX for Dupuytren's contracture in 2011 and for Peyronie's disease in 2015. The United Kingdom and France have relatively stronger use within public health systems. Germany remains constrained because treatment may require imports from the United States. Italy's experience with more than 2,200 patients provides a sizable clinical reference for regional discussions on access.

Asia-Pacific is forecasted to grow at a 9.24% CAGR through 2031, the highest regional rate in the collagenase Clostridium histolyticum market. A 2024 study reported that the total number of treated patients fell 43%, while surgical volumes rose to 1.5 times the 2019 level. This experience indicates that demand may remain untreated when enzymatic therapy is unavailable. Regulatory progress in Japan and China, together with growing specialist communities in Australia, South Korea, and India, can support future uptake. The rest of the world, including regions like the Middle East, Africa, and South America, remains early-stage regions, with private healthcare development offset by regulatory and cold-chain constraints.

List of Companies Covered in this Report:

• Abbvie
• Amano Enzyme Inc.
• BioSpecifics Technologies Corp.
• Endo International
• Horizon Therapeutics
• Ipsen
• Keenova Therapeutics plc
• MediWound Ltd.
• Nordmark Arzneimittel GmbH & Co. KG
• Recordati Rare Diseases
• Revance Therapeutics, Inc.
• Sanofi
• Swedish Orphan Biovitrum
• Teva Pharmaceutical Industries
• Worthington Biochemical Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support